Get the Stockscreener App
71.96
2.95%
2.06
After Hours:
69.68
-2.28
-3.17%
Disc Medicine Inc stock is traded at $71.96, with a volume of 428.20K.
It is up +2.95% in the last 24 hours and up +20.29% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$69.90
Open:
$70.21
24h Volume:
428.20K
Relative Volume:
1.22
Market Cap:
$2.50B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-19.61
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
+3.87%
1M Performance:
+20.29%
6M Performance:
+85.80%
1Y Performance:
+50.70%
1-Day Range:
$69.50
$72.31
1-Week Range:
$67.22
$72.68
52-Week Range:
$30.82
$72.68
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
71.96 | 2.43B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Can Disc Medicine Inc. stock weather global recessionJuly 2025 News Drivers & Weekly Chart Analysis and Trade Guides - newser.com
How Disc Medicine Inc. stock performs in interest rate cyclesQuarterly Profit Review & Detailed Earnings Play Alerts - newser.com
Backtesting results for Disc Medicine Inc. trading strategiesPortfolio Performance Report & High Return Trade Guides - newser.com
Is Disc Medicine Inc. stock trading near support levelsEarnings Beat & Safe Entry Zone Identification - newser.com
What MACD and RSI say about Disc Medicine Inc.July 2025 Institutional & Safe Capital Investment Plans - newser.com
Kevin Bitterman Sells 18,039 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Price action breakdown for Disc Medicine Inc.Weekly Stock Summary & High Accuracy Investment Entry Signals - newser.com
Tick level data insight on Disc Medicine Inc. volatilityPortfolio Value Summary & Daily Entry Point Alerts - newser.com
Real time social sentiment graph for Disc Medicine Inc.July 2025 Review & Real-Time Market Sentiment Alerts - newser.com
Disc Medicine's (IRON) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Bitterman Kevin, director at Disc Medicine, sells $6.3m in shares - Investing.com Canada
Building trade automation scripts for Disc Medicine Inc.July 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
Using RSI to spot recovery in Disc Medicine Inc.Quarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
Visual trend scoring systems applied to Disc Medicine Inc.2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com
Momentum divergence signals in Disc Medicine Inc. chartTrade Analysis Summary & Reliable Price Breakout Alerts - newser.com
Real time pattern detection on Disc Medicine Inc. stockDip Buying & Reliable Entry Point Alerts - newser.com
Quantitative breakdown of Disc Medicine Inc. recent moveQuarterly Earnings Summary & Daily Oversold Bounce Ideas - newser.com
Disc Medicine (NASDAQ:IRON) Sets New 52-Week HighTime to Buy? - MarketBeat
Disc Medicine stock hits 52-week high at 69.38 USD By Investing.com - Investing.com Nigeria
Disc Medicine director Mona Ashiya resigns, board size reduced to eight - Investing.com
Disc Medicine Board Member Mona Ashiya Resigns - TipRanks
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Disc Medicine stock hits 52-week high at 69.38 USD - Investing.com
Identifying reversal signals in Disc Medicine Inc.Market Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Is Disc Medicine Inc. stock cheap at current valuationPortfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Developing predictive dashboards with Disc Medicine Inc. data2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is Disc Medicine Inc. showing signs of accumulation2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is a relief rally coming for Disc Medicine Inc. holdersEarnings Miss & Stock Portfolio Risk Management - newser.com
What momentum shifts mean for Disc Medicine Inc.Weekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Will Disc Medicine Inc. stock recover after recent dropEarnings Growth Summary & Daily Technical Forecast Reports - newser.com
Should you wait for a breakout in Disc Medicine Inc.2025 Market Outlook & Expert Curated Trade Setups - newser.com
Analyzing Disc Medicine Inc. with risk reward ratio charts2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
A Fresh Look at Disc Medicine’s Valuation After Bitopertin NDA Submission and Positive Phase 2 Data - Yahoo Finance
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) - Sahm
Disc MedicineBiotech Stock On The Move With Multiple Near-Term Catalysts - RTTNews
Disc Medicine (NASDAQ:IRON) Sets New 1-Year HighHere's Why - MarketBeat
Disc Medicine submits NDA for bitopertin in erythropoietic porphyria By Investing.com - Investing.com Nigeria
Disc Medicine Announces Submission of New Drug Application - GlobeNewswire
Disc Medicine Announces Submission Of NDA For Bitopertin - Nasdaq
Disc Medicine Submits New Drug Application to FDA for Bitopertin to Treat Patients With Erythropoietic Protoporphyria - MarketScreener
Disc Medicine submits NDA for bitopertin in erythropoietic porphyria - Investing.com
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Disc Medicine Inc Stock (IRON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Kevin | Director |
Oct 07 '25 |
Sale |
68.38 |
18,039 |
1,233,493 |
572,582 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):